Dr. Jared Weiss of the University of North Carolina addressed the Acquired Resistance in Lung Cancer Patient Forum with information on what patients' options are when their ALK, ROS1 or EGFR lung cancer progresses.
Logo
You are here
Life After 1st Line Targeted Therapy: What Next?
Related Content
Video
Dr. Mojun Zhu joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community.
In this video, Dr. Zhu discusses if immunotherapy can help patients with small cell lung cancer.
*****
Zhu Mojun Zhu博士加入GRACE任客座教授，为普通话社区提供最新信息，以向我们的普通话肺癌视频库提供信息。 在此视频中，朱博士讨论了免疫疗法是否可以帮助小细胞肺癌患者。
Video
Dr. Mojun Zhu joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community.
In this video, Dr. Zhu discusses if immunotherapy can help frail patients with advanced NSCLC.
*****
Zhu Mojun Zhu博士加入GRACE任客座教授，为普通话社区提供最新信息，以向我们的普通话肺癌视频库提供信息。 朱医生在这段视频中讨论了免疫疗法是否可以帮助弱势的晚期非小细胞肺癌患者。
要加入对话，请访问https://cancergrace.org/forum。
Video
Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community.
In this video, Dr. Li discusses which patients with advanced NSCLC are good candidates for first line immunotherapy alone today.
******
李仁妮博士加入GRACE，担任客座教授，为普通话社区提供最新信息给我们的普通话肺癌视频库。 在此视频中，李医生讨论了哪些晚期NSCLC患者今天仅是一线免疫治疗的好人选。